Cargando…
Tumor immune microenvironment in epidermal growth factor receptor-mutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment: a narrative review
OBJECTIVE: To review and summarize the characteristics of the tumor immune microenvironment (TIME) in EGFR-mutated non-small cell lung cancer (NSCLC) after EGFR-TKI treatment and its role in TKI resistance. BACKGROUND: Lung cancer is one of the most commonly diagnosed cancer and the leading cause of...
Autores principales: | Liu, Lihui, Wang, Chao, Li, Sini, Bai, Hua, Wang, Jie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8512456/ https://www.ncbi.nlm.nih.gov/pubmed/34733631 http://dx.doi.org/10.21037/tlcr-21-572 |
Ejemplares similares
-
The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
por: Chang, Shih-Chieh, et al.
Publicado: (2011) -
Epidermal growth factor receptor tyrosine kinase inhibitors
por: Ranson, M
Publicado: (2004) -
Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?
por: Banno, Eri, et al.
Publicado: (2016) -
Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types
por: Park, Sojung, et al.
Publicado: (2021) -
A case of epidermal growth factor receptor tyrosine kinase inhibitor effectiveness in epidermal growth factor receptor mutation-positive squamous cell carcinoma
por: Matsumura, Sosuke, et al.
Publicado: (2023)